Cure My Disease

Don't miss your cure!

 Log in / Sign up

Precision radiation boost aims to improve prostate cancer control

NCT ID NCT01508390

Ongoing Disease control Sponsor: Boston Medical Center Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests whether a precise, high-dose radiation boost using CyberKnife can improve outcomes for men with high-risk prostate cancer that has not spread. Participants receive standard hormone therapy and radiation to the prostate and nearby lymph nodes, followed by a CyberKnife boost to the prostate alone. The trial tracks how long the cancer stays under control and how the treatment affects quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CyberKnife stereotactic body radiation therapy
What this could lead to
If successful, this approach could offer a more precise radiation boost for high-risk prostate cancer, potentially improving disease control while reducing side effects.
What could go wrong
This is a small, early-phase study (35 participants) without a comparison group, so results may not be definitive. Radiation can still cause side effects like urinary or bowel issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

  • Boston Medical Center

    Boston, Massachusetts, 02118, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.